Omicron-Specific Sinopharm COVID Vaccine Candidates Cleared for Clinical Trial

BEIJING (Reuters) – Two COVID-19 vaccine candidates developed by units of China National Biotec Group (CNBG) to target the Omicron variant were approved for clinical trials as boosters in Hong Kong, the Sinopharm subsidiary said on Saturday. Scientists worldwide are racing to study upgraded injections against Omicron, as data indicated that antibodies elicited by vaccines …

Omicron-Specific Sinopharm COVID Vaccine Candidates Cleared for Clinical Trial Read More »